In addition, recent research indicates that inhibiting the TXNIP/NLRP3 inflammasome can mitigate LPS‐induced ALI, suggesting that the NLRP3 inflammasome is a potential therapeutic target for inflammatory diseases [11, 14, 15, 16, 17]. Here, NLRP3 is linked to acute respiratory distress syndrome.